Dyne Therapeutics, Inc. (DYN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Dyne Therapeutics, Inc. (DYN) closed at USD 15.04 on 2026-10-14, a change of -38.1 % over the past year, with a market capitalization of USD 2.86B.

Dyne Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Dyne Therapeutics, Inc. key figures

Previous close

USD 15.04 (2026-10-14)

1-year change

-38.1 %

Market cap

USD 2.86B

Enterprise value

USD 2.19B

P/E ratio (trailing)

-4.63

P/E ratio (forward)

-4.58

EPS (trailing)

-3.30

EPS (forward)

-3.34

PEG ratio

n/a

Price to book

3.61

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.25

Employees

289

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Dyne Therapeutics, Inc. and compare it with other stocks.